We are very proud to share this article from the Austrian newspaper Kurier, in which the research and development activities and the further strategic planning of Vaccentis are discussed in an interview with our Head of Research & Development Ingrid Rauter and our CEO Martin Munte.
Link: Neue Impfung gegen Krebs: Zulassung in wenigen Jahren realistisch
